Loading company
Eikon Therapeutics, Inc.
EIKN · Nasdaq · ·
$7.92+0.1%Sep 29 close
- 1M
- -27.9%
- 6M
- -18.2%
EIKN · Nasdaq · ·
$7.92+0.1%Sep 29 close
From the company’s own 8-K filing.
Eikon Therapeutics, Inc. has no earnings call transcript available.
“The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for presentation at the upcoming ESMO conference in October in Madrid,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates that could eventually become lifesaving medicines. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Eikon Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.